{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:22:46Z","timestamp":1787844166456,"version":"build-2784847793"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:sec>\n                    <jats:title>BACKGROUND AND OBJECTIVES:<\/jats:title>\n                    <jats:p>Efficient stem cell collection from pediatric donors is a common challenge for allogeneic hematopoietic stem cell transplants (HSCT). The addition of plerixafor, a CXCR4 antagonist to standard stem cell mobilization regimens has shown success. We describe our experience with the usage of a single dose of plerixafor in addition to granulocyte colony-stimulating factor (G-CSF) in healthy pediatric stem cell donors for patients undergoing HSCT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS:<\/jats:title>\n                    <jats:p>A retrospective review of the safety and efficacy of plerixafor, used in pediatric stem cell donors for aiding stem cell mobilization, was done. Data from 14 pediatric donors who received plerixafor in addition to standard G-CSF were studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>Plerixafor was well tolerated by all donors with no major adverse effects. All donors showed robust peripheral blood stem cell mobilization, enabling an adequate stem cell collection with single apheresis, even in scenarios with an unfavorable donor\/patient body weight ratio.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>The use of plerixafor can be encouraged in pediatric donors to optimize apheresis outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ajts.ajts_32_24","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T04:00:39Z","timestamp":1737691239000},"page":"170-172","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of plerixafor in CD34+ stem cell mobilization in healthy pediatric stem cell donors"],"prefix":"10.4103","volume":"20","author":[{"given":"Rishab","family":"Bharadwaj","sequence":"first","affiliation":[{"name":"Department of Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Dr. Rela Institute and Medical Centre, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vimal","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Dr. Rela Institute and Medical Centre, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti","family":"Sachan","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, Dr. Rela Institute and Medical Centre, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepthi","family":"Krishna","sequence":"additional","affiliation":[{"name":"Department of Transfusion Medicine, Dr. Rela Institute and Medical Centre, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deenadayalan","family":"Munirathnam","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Dr. Rela Institute and Medical Centre, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"R1-20260529","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1517\/14712598.8.11.1797","article-title":"Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells","volume":"8","author":"Uy","year":"2008","journal-title":"Expert Opin Biol Ther"},{"key":"R2-20260529","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2147\/JBM.S307520","article-title":"Use of plerixafor for stem cell mobilization in the setting of autologous and allogeneic stem cell transplantations:An update","volume":"12","author":"Bilgin","year":"2021","journal-title":"J Blood Med"},{"key":"R3-20260529","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1182\/blood-2008-08-174946","article-title":"Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma","volume":"113","author":"DiPersio","year":"2009","journal-title":"Blood"},{"key":"R4-20260529","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1038\/s41409-020-0836-2","article-title":"Plerixafor combined with standard regimens for hematopoietic stem cell mobilization in pediatric patients with solid tumors eligible for autologous transplants:Two-arm phase I\/II study (MOZAIC)","volume":"55","author":"Morland","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"R5-20260529","doi-asserted-by":"crossref","first-page":"e976","DOI":"10.1634\/theoncologist.2019-0898","article-title":"EMA Recommendation for the pediatric indications of plerixafor (Mozobil) to enhance mobilization of hematopoietic stem cells for collection and subsequent autologous transplantation in children with lymphoma or malignant solid tumors","volume":"25","author":"Karres","year":"2020","journal-title":"Oncologist"},{"key":"R6-20260529","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/j.1365-2141.2008.07529.x","article-title":"Peripheral blood progenitor cell collection adverse events for childhood allogeneic donors:Variables related to the collection and safety profile","volume":"144","author":"Sevilla","year":"2009","journal-title":"Br J Haematol"},{"key":"R7-20260529","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3324\/haematol.2016.147132","article-title":"Effect of high-dose plerixafor on CD34(+) cell mobilization in healthy stem cell donors:Results of a randomized crossover trial","volume":"102","author":"Pantin","year":"2017","journal-title":"Haematologica"},{"key":"R8-20260529","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/jca.21844","article-title":"Plerixafor-based mobilization in pediatric healthy donors with unfavorable donor\/recipient body weight ratio resulted in a better CD34(+) collection yield:A retrospective analysis","volume":"36","author":"Zubicaray","year":"2021","journal-title":"J Clin Apher"},{"key":"R10-20260529","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.bbmt.2018.06.023","article-title":"Differences in cellular composition of peripheral blood stem cell grafts from healthy stem cell donors mobilized with either granulocyte colony-stimulating factor (G-CSF) alone or G-CSF and plerixafor","volume":"24","author":"Teipel","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"R11-20260529","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/bmt.2014.330","article-title":"Mobilized peripheral blood grafts include more than hematopoietic stem cells:The immunological perspective","volume":"50","author":"Saraceni","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"R12-20260529","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/trf.15037","article-title":"The feasibility and efficacy of subcutaneous plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA-identical sibling donors:Results of the HOVON-107 study","volume":"59","author":"de Greef","year":"2019","journal-title":"Transfusion"},{"key":"R13-20260529","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1182\/bloodadvances.2018027599","article-title":"Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells","volume":"3","author":"Chen","year":"2019","journal-title":"Blood Adv"}],"container-title":["Asian Journal of Transfusion Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ajts.ajts_32_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T15:12:46Z","timestamp":1787843566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ajts.ajts_32_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,24]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ajts.ajts_32_24","relation":{},"ISSN":["0973-6247","1998-3565"],"issn-type":[{"value":"0973-6247","type":"print"},{"value":"1998-3565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,24]]},"assertion":[{"value":"2024-02-22","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}